MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
29.66
-0.47
-1.56%
After Hours: 29.66 0 0.00% 19:30 09/04 EDT
OPEN
29.64
PREV CLOSE
30.13
HIGH
30.10
LOW
29.40
VOLUME
736.98K
TURNOVER
--
52 WEEK HIGH
31.74
52 WEEK LOW
10.55
MARKET CAP
3.78B
P/E (TTM)
-7.5966
1D
5D
1M
3M
1Y
5Y
1D
Arcus Biosciences Advances Casdatifan With New Liver Function Study
TipRanks · 1d ago
Weekly Report: what happened at RCUS last week (0824-0828)?
Weekly Report · 5d ago
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Barchart · 08/26 15:05
Why Arcus Biosciences (RCUS) Is Getting Attention Today
Simply Wall St · 08/25 16:21
Weekly Report: what happened at RCUS last week (0817-0821)?
Weekly Report · 08/24 09:58
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales
Simply Wall St · 08/20 19:26
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
PR Newswire · 08/19 23:58
Weekly Report: what happened at RCUS last week (0810-0814)?
Weekly Report · 08/17 09:59
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.